Developing and advancing innovative solutions in nuclear medicine technology drives us.
Come explore our solutions.
NorthStar is focused on providing a spectrum of non-uranium based solutions for medical radioisotope supply. Our state-of-the-art facilities, both current and planned, serve as the platform for exciting new developments in molybdenum-99 production, with potential pipeline applications for additional important medical radioisotopes.
NorthStar continues to invest heavily in our non-uranium based processing and production capabilities for Mo-99 to ensure adequate capacity. Ongoing research is underway to explore alternative approaches to irradiation and include our accelerator program which uses accelerator technology rather than a nuclear reactor.
NorthStar recently completed installation and qualification of two state-of-the-art Von Gahlen Mo-99 filling systems at our NorthStar facility in Columbia, Missouri. This allows NorthStar to supply a meaningful volume of Mo-99 to the U.S. market.
The RadioGenix® System (technetium Tc 99m generator) is a proprietary, patented platform technology with potential pipeline applications including alpha therapies such as actinium-225 / bismuth-213, and beta therapies such as tungsten-188 / rhenium-188, germanium-68 / gallium-68, among others.